JWA
RNTX

JFS Wealth Advisors’s Rein Therapeutics RNTX Stock Holding History

JFS Wealth Advisors’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.65K Hold
1,590
– – ﹤0.01% 1664
2026
Q1 		$2.07K Hold
1,590
– – ﹤0.01% 1496
2025
Q4 		$1.84K Hold
1,590
– – ﹤0.01% 1573
2025
Q3 		$1.82K Hold
1,590
– – ﹤0.01% 1461
2025
Q2 		$2.23K Hold
1,590
– – ﹤0.01% 1368
2025
Q1 		$2.81K Hold
1,590
– – ﹤0.01% 1338
2024
Q4 		$3.66K Hold
1,590
– – ﹤0.01% 1243
2024
Q3 		$5.63K Hold
1,590
– – ﹤0.01% 1080
2024
Q2 		$4.41K Hold
1,590
– – ﹤0.01% 1120
2024
Q1 		$10.5K Hold
1,590
– – ﹤0.01% 799
2023
Q4 		$4.85K Hold
1,590
– – ﹤0.01% 1069
2023
Q3 		$2.42K Hold
1,590
– – ﹤0.01% 1288
2023
Q2 		$2.85K Hold
1,590
– – ﹤0.01% 1248
2023
Q1 		$1.97K Hold
1,590
– – ﹤0.01% 1372
2022
Q4 		$3.77K Hold
1,590
– – ﹤0.01% 1109
2022
Q3 		$7K Hold
1,590
– – ﹤0.01% 885
2022
Q2 		$8K Hold
1,590
– – ﹤0.01% 850
2022
Q1 		$16K Hold
1,590
– – ﹤0.01% 668
2021
Q4 		$18K Hold
1,590
– – ﹤0.01% 592
2021
Q3 		$32K Buy
+1,590
New +$34.8K ﹤0.01% 478

Other funds holding RNTX

SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
CPIG
Chicago Partners Investment Group Chicago, Illinois $5B AUM 26.84% 1-Year Est. Return
GG
Gleason Group Prospect, Kentucky $1.15B AUM 21.11% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

JFS Wealth Advisors's RNTX Position: Q2 2026 in Review

JFS Wealth Advisors held its Rein Therapeutics (RNTX) position steady in Q2 2026 at 1,590 shares worth $1.65K. The position accounts for ﹤0.01% of the portfolio, ranked #1664.

JFS Wealth Advisors first reported a position in RNTX in Q3 2021 and has held it in 20 quarters since. The position peaked at $32K in Q3 2021. 6 funds tracked by Wall St. Rank hold RNTX as of Q2 2026.

  • JFS Wealth Advisors held 1,590 shares of Rein Therapeutics worth $1.65K as of Q2 2026.
  • JFS Wealth Advisors left its Rein Therapeutics share count unchanged in Q2 2026.
  • Rein Therapeutics made up ﹤0.01% of JFS Wealth Advisors's portfolio in Q2 2026, its #1664 holding.
  • JFS Wealth Advisors first reported a position in Rein Therapeutics in Q3 2021 and has held it in 20 quarters since.
  • JFS Wealth Advisors's Rein Therapeutics position peaked at $32K in Q3 2021.
  • 6 funds tracked by Wall St. Rank held Rein Therapeutics as of Q2 2026.

Based on JFS Wealth Advisors's 13F filing for Q2 2026, filed 10 Jul 2026.